Summary of the Conference Call on Brain-Computer Interface Industry Industry Overview - The conference focused on the brain-computer interface (BCI) industry, which has gained significant attention since the beginning of the year, reflecting a core trend in the industry rather than just a thematic investment opportunity [2][3]. - The BCI technology can be categorized into invasive, semi-invasive, and non-invasive types based on the location of the brain signal acquisition [2][3]. Key Points and Arguments - The BCI fundamentally aims to achieve interaction between the human brain and machines, allowing for the recognition and manipulation of external devices through brain signals [3]. - The core technological barriers in BCI development include signal acquisition, encoding, and decoding, particularly in invasive BCI systems where stability and precision are critical [3][4]. - The BCI market is currently valued at approximately $2.62 billion, with projections to reach $2.94 billion by 2025 and $12.4 billion by 2034, indicating a compound annual growth rate (CAGR) of 17.35% [7]. - The primary therapeutic applications of BCI include treatment for motor function disorders, sensory deficits, and neurological diseases such as epilepsy, Parkinson's, and Alzheimer's [5][6]. Market Potential - The global market for BCI is seen as a blue ocean with significant potential, particularly in rehabilitation for stroke patients and visual impairment, with over 10 million individuals in China suffering from irreversible vision loss [8][9]. - The BCI industry is expected to expand into various sectors, including industrial applications, consumer products, and healthcare, with a focus on both serious medical applications and consumer health monitoring devices [11][12]. Regulatory and Policy Environment - There is a lack of approved invasive BCI products globally, with no products having received NMPA certification in China, which poses a challenge for market entry [13]. - Recent government policies have included BCI in strategic planning, with several provinces establishing pricing standards for BCI devices, although reimbursement policies vary significantly across regions [19][20]. Competitive Landscape - Notable companies in the BCI space include Neuralink, which is leading in commercialization efforts, and other firms like Medtronic and Abbott that have been involved in neurostimulation products for years [5][21]. - The conference highlighted the importance of clinical trials and the potential for breakthrough products to gain FDA approval, which could catalyze investment interest in the sector [18][25]. Future Directions - The BCI industry is moving towards minimally invasive technologies, with a focus on high bandwidth and non-invasive solutions [14][24]. - The conference concluded with an emphasis on the need for continued innovation and exploration in the BCI field, particularly in addressing ethical considerations and overcoming technological barriers [12][13]. Additional Insights - The BCI market is still in its early stages compared to other investment themes, but there is a growing interest from both primary and secondary markets in developing BCI-related products [26][27]. - The potential for BCI to transform rehabilitation and treatment for various neurological conditions presents a compelling investment opportunity for stakeholders in the healthcare and technology sectors [27].

Core Viewpoint - The Hong Kong stock market showed strong performance in the healthcare sector, particularly in innovative drugs and medical companies, with significant gains observed in various stocks [1] Group 1: Market Performance - The Hong Kong stock market experienced fluctuations but ultimately strengthened, with notable performances in the innovative drug and medical sectors [1] - Stocks such as CSPC Pharmaceutical Group and Innovent Biologics rose over 6%, while others like Zai Lab and WuXi Biologics increased by more than 5% [1] - The Hong Kong Stock Connect Medical ETF (159506) saw a rise of over 3% during trading [1] Group 2: Industry Insights - At the J.P. Morgan Healthcare Conference held in January, global pharmaceutical companies disclosed advanced research pipelines and significant business development transactions, creating clear order expectations for the CXO industry [1] - The penetration of AI in healthcare is accelerating, with applications expanding from smart consultations to chronic disease management, leading to a reevaluation of the value of internet healthcare platforms like Alibaba Health and JD Health [1] - Analysts suggest that the current healthcare sector presents multiple investment opportunities, with the CXO industry benefiting from a recovery in overseas orders and domestic capacity clearance [1] - The medical device sector is supported by domestic equipment upgrade policies and overseas market expansion, with cutting-edge areas like brain-computer interfaces and AI imaging continuously catalyzing growth [1] - Internet healthcare is optimizing operational efficiency against the backdrop of deepening medical insurance payment reforms, leading to a clearer profitability growth trajectory [1] Group 3: ETF Information - The Hong Kong Stock Connect Medical ETF (159506) closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug and Healthcare Index (HSSCHI) [2] - The index composition emphasizes companies with high R&D expenditure and innovative drug business, ensuring that companies with the lowest average R&D to revenue ratio over the past two years are excluded [2] - This innovative focus aids investors in accurately capturing investment opportunities within the Hong Kong pharmaceutical sector [2]

Group 1 - The Hong Kong stock market saw a strong performance in innovative pharmaceutical stocks, with CSPC Pharmaceutical Group rising over 7%, Kelun-Bio increasing more than 6%, and Innovent Biologics up over 5% [1] - The related ETFs for innovative pharmaceuticals in Hong Kong experienced gains of over 3% [1] Group 2 - Multiple investment opportunities are present in the current healthcare sector, driven by the recovery of overseas orders and domestic capacity clearance in the CXO industry, leading to sustained improvement in market conditions and potential for valuation recovery [2] - The medical device sector benefits from domestic equipment upgrade policies and expansion into overseas markets, with continuous catalysts in cutting-edge areas such as brain-computer interfaces and AI imaging [2] - Internet healthcare is seeing improved operational efficiency and clearer profit growth trajectories amid deepening reforms in medical insurance payment systems [2]

Group 1 - The Hong Kong stock market for pharmaceuticals and healthcare has shown a strong upward trend since February, with notable performance from ETFs such as the Hong Kong Innovation Drug ETF (520880) and the Hong Kong Healthcare ETF (159137), both achieving six consecutive days of gains [1] - The total transaction scale for China's innovative drug License-out is projected to reach a record $135.7 billion by 2025, with significant collaborations occurring in early 2026, validating the global value of domestic innovative drug pipelines [1] - The Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," indicating a shift towards commercial realization of pipeline expectations, with many quality stocks showing attractive valuation ratios [1] Group 2 - The Hong Kong Innovation Drug ETF (520880) and its associated fund (025221) focus entirely on innovative drug research and development companies, with the top ten weighted stocks accounting for over 73% of the portfolio, highlighting its leading attributes [2] - The Hong Kong Healthcare ETF (159137) targets medical innovation, encompassing trending concepts such as brain-computer interfaces, AI healthcare, and online pharmacies, while also covering leading companies across the entire innovative drug industry chain [2]

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [2][6]. Core Insights - The medical device procurement scale is experiencing a partial decline due to high base effects, but there are opportunities in the surgical robot market [2]. - The report emphasizes that the ongoing implementation of equipment upgrade policies is expected to drive long-term procurement levels in the medical device sector, recommending companies that are likely to benefit from these policies [4]. - The report highlights that the four ministries jointly issued a notice in 2024 aiming for a more than 25% increase in medical equipment investment by 2027 compared to 2023, which is expected to enhance the configuration of high-end equipment to levels comparable to middle-income countries [6]. Summary by Sections Investment Recommendations - The report suggests maintaining an "Overweight" rating and recommends companies likely to benefit from the equipment upgrade policies, including Mindray Medical, United Imaging, Kaili Medical, Aohua Endoscopy, and Jingfeng Medical-B. It also suggests paying attention to MicroPort Scientific-B [6]. Monthly Procurement Data - In January 2026, the procurement scale for new devices showed a year-on-year decline: MR down 22.6%, CT down 25.6%, DR down 18.2%, ultrasound down 10.1%, while endoscopy grew by 1.1%, and surgical robots declined by 20.1%. Company-specific performance showed United Imaging MR down 36.5%, United Imaging CT up 8.5%, Mindray ultrasound up 10.9%, Kaili ultrasound down 14.8%, Kaili endoscopy up 55.4%, and Aohua endoscopy down 11.7% [6]. Policy Impact - The report discusses the release of a guideline by the National Healthcare Security Administration on January 20, 2026, which establishes a unified pricing project for surgical robots, expected to accelerate the penetration and application of robotic surgery technology [6].

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Group 1: Emerging Fields - The release of 5 national standards in emerging fields such as brain-computer interfaces and digital twins aims to clarify reference frameworks and data formats, supporting high-quality development in cutting-edge technology [1] - 47 national standards related to aluminum nitride single crystal polishing sheets and carbon fiber reinforced composites are published to promote innovation in the new materials industry [1] - 15 national standards for experimental animals, including identification and evaluation techniques, are introduced to better support biotechnological research and applications [1] Group 2: Transportation and Logistics - 2 national standards for intelligent connected vehicles are published, focusing on performance testing for autonomous driving and parking systems, enhancing vehicle performance and safety [1] - 6 national standards related to automotive door handles and adaptive cruise control systems are released to improve road traffic safety and sustainability [1] - 2 mandatory national standards for postal services address safety production operations and equipment requirements, enhancing safety governance in the postal and express delivery sectors [1] Group 3: Ecological and Environmental Protection - 6 national standards, including general requirements for natural protected area signs and drone inspection techniques for forest and grassland fire prevention, are established to support national ecological security [2] - 2 national standards for environmental due diligence assessments and environmental report verification are introduced to promote green development and enhance environmental governance effectiveness [2] - 2 national standards related to greenhouse gas emission accounting and reporting requirements are published to assist companies in accurately calculating and reporting emissions [2] Group 4: Safety Production - 16 mandatory national standards in the fire safety sector, including outdoor fire hydrants and combustible gas detectors, are updated to provide technical guidelines for mitigating major fire safety risks [2] - 14 national standards for special equipment, such as gantry cranes and pressure vessels, are released to ensure safe and stable operation [2] Group 5: Public Life - 4 national standards for services for people with disabilities, including single-arm walking aids and cognitive accessibility, are published to enhance the quality of rehabilitation aids and services for vulnerable groups [2] - 8 national standards related to medical laboratory quality and medical device sterilization processes are introduced to regulate practices in medical testing and manufacturing [2] Group 6: Additional Standards - The market regulatory authority also released national standards concerning transportation terminology, earth-moving machinery, and reciprocating internal combustion engines [3]

Core Viewpoint - The National Standardization Administration has approved a series of important national standards aimed at promoting high-quality development across various sectors, including emerging technologies, transportation logistics, ecological protection, safety production, and public welfare [1][7]. Emerging Fields - Five national standards have been released for brain-computer interfaces and digital twins, clarifying reference frameworks and data formats to support high-quality development in cutting-edge technology [3][8]. - Forty-seven national standards have been established for aluminum nitride single crystal polishing wafers and carbon fiber reinforced composites, fostering innovation in the new materials industry [3][8]. - Fifteen national standards related to animal model identification and evaluation techniques, as well as skin pathogenic fungi detection methods, have been published to better support biotechnological research and applications [3][8]. Transportation and Logistics - Two national standards for intelligent connected vehicles have been released, focusing on performance testing for autonomous driving and parking systems, enhancing vehicle performance and safety [3][8]. - Six national standards concerning automotive door handles and adaptive cruise control systems have been introduced to improve road traffic safety and sustainability [3][8]. - Two mandatory national standards for postal safety operations and equipment configuration have been established, outlining safety protocols for postal and express delivery services [3][8]. - Four logistics procurement national standards have been published to promote green transformation in supply chains [3][8]. Ecological Protection - Six national standards have been released, including general requirements for natural protected area signage and technical specifications for drone inspections in forest and grassland fire prevention, providing standard support for national ecological security [4][9]. - Two national standards for environmental due diligence assessments and environmental report verification have been published, significantly contributing to green development and enhancing environmental governance effectiveness [4][9]. - Two national standards related to greenhouse gas emission accounting and reporting requirements have been established to assist companies in accurately calculating and reporting their emissions [4][9]. Safety Production - Sixteen mandatory national standards in the fire safety sector have been released, updating technical requirements and inspection rules for fire safety products to mitigate major fire safety risks [4][9]. - Fourteen national standards for special equipment, including gantry cranes and pressure vessels, have been published to ensure the safe and stable operation of such equipment [4][9]. Public Welfare - Four national standards for services related to disabled individuals, including single-arm walking aids and autism rehabilitation institutions, have been introduced to enhance the quality of rehabilitation aids and standardize services for vulnerable groups [5][9]. - Eight national standards have been established to regulate medical laboratory quality and capabilities, as well as the sterilization processes for medical devices [5][9]. Additional Standards - The National Standardization Administration has also released national standards concerning transportation terminology, earth-moving machinery, and reciprocating internal combustion engines [5][10].

Core Viewpoint - The company Aihuilong (688575.SH) is under investigation by the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure laws, which has led to a decline in its stock price and raised concerns about its strategic partnership with Brain Machine Star Chain Technology Co., Ltd. [1][5] Group 1: Investigation and Stock Impact - On February 6, Aihuilong received a notice from the CSRC regarding an investigation due to misleading statements related to a strategic cooperation framework agreement signed with Brain Machine Star Chain [1][5] - Following the announcement of the partnership, Aihuilong's stock price fell by 2.98% to 14.02 yuan per share, with a significant increase in trading volume [1][3] - The Shanghai Stock Exchange issued a regulatory warning to Aihuilong, emphasizing the need for accurate and complete information disclosure, especially given the market's heightened interest in brain-machine interface technology [3][4] Group 2: Business Operations and Financial Forecast - Aihuilong's main business involves the research, production, and sales of in vitro diagnostic instruments and related reagents, covering various medical fields [6] - The company expects a significant decline in net profit for 2025, projecting a decrease of approximately 90.05% to 93.37% compared to 2024, with net profit estimated between 20 million to 30 million yuan [6][7] - The decline in profit is attributed to reduced domestic market demand due to industry policies, leading to decreased revenue and gross margin [6][7] Group 3: Strategic Partnership Details - Aihuilong announced a strategic partnership with Brain Machine Star Chain to develop brain-machine interface products, focusing on non-invasive technology [4] - The estimated investment for the collaboration is around 30 million yuan, with Aihuilong's investment not exceeding 15 million yuan [4] - Brain Machine Star Chain, established in September 2025, has a registered capital of 5 million yuan and claims to focus on both non-invasive and invasive brain-machine interface technologies [4]

Group 1 - The China Securities Regulatory Commission (CSRC) has initiated investigations into two companies, Shenzhen Yahui Long Biotechnology Co., Ltd. (Yahui Long) and Changzhou Tiansheng New Materials Group Co., Ltd. (Tiansheng New Materials), for suspected violations of information disclosure laws [1][6] - Yahui Long's investigation is linked to misleading statements regarding a strategic cooperation framework agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. amid the "brain-machine interface" market trend [2][4] - Tiansheng New Materials is under investigation for potential undisclosed related party transactions from the 2023 fiscal year [7] Group 2 - Following the announcement of the strategic cooperation with Brain Machine Star Chain, Yahui Long's stock price rose by 6.52% on January 6, with trading volume increasing by 299% compared to the previous trading day [5] - Yahui Long's subsequent disclosures revealed that Brain Machine Star Chain's products are still in early research and development stages, and the company lacks systematic commercialization capabilities [3] - The Shanghai Stock Exchange issued a warning to Yahui Long for inconsistent statements regarding the technical paths of its cooperation partner, emphasizing the need for accurate and complete information disclosure [3][4] Group 3 - ST Funeng (福能东方装备科技股份有限公司) received an administrative penalty from the Guangdong Securities Regulatory Bureau for information disclosure violations, including inflated profits through fictitious transactions [8] - The penalty included a warning and a fine of 6.5 million yuan, with the company required to correct its disclosures [8]